high risk myelodysplastic syndrome

Showing 1 - 15 of 15

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in

Recruiting
  • Acute Myeloid Leukemia
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston

Completed
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 21, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia

Completed
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +14 more
  • Aldesleukin
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 31, 2022

Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of

Active, not recruiting
  • Acute Myeloid Leukemia With Multilineage Dysplasia
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 25, 2022

Hematopoietic and Lymphoid Cell Tumor, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome Trial in Houston

Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +13 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 8, 2022

High Risk Myelodysplastic Syndrome Trial in Houston (Guadecitabine)

Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Feb 2, 2022

Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow

Recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2022

Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute

Recruiting
  • Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 27, 2021

Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in

Completed
  • Relapsed or Refractory Haematological Malignancies Including
  • +10 more
  • Aachen, Germany
  • +11 more
Oct 21, 2021

Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in

Completed
  • Acute Myeloid Leukemia
  • +5 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 4, 2021

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia-2, High Risk Myelodysplastic Syndrome Trial in New Haven, Baltimore,

Completed
  • Acute Myeloid Leukemia
  • +3 more
  • New Haven, Connecticut
  • +2 more
Oct 10, 2020

Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome Trial in Houston (Azacitidine, Cytarabine, Tosedostat)

Terminated
  • Acute Myeloid Leukemia
  • High Risk Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Apr 9, 2020

Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome Trial in United Kingdom (Plerixafor, AC220, Ganetespib)

Completed
  • Acute Myeloid Leukaemia
  • High Risk Myelodysplastic Syndrome
  • Aberdeen, United Kingdom
  • +12 more
Jun 10, 2014